Published • loading... • Updated
Sanofi Under Scrutiny: EU Probes Vaccine Marketing Tactics
The EU executive says Sanofi may have disparaged CSL Seqirus’s Fluad in a campaign targeting doctors, and a fine could follow if abuse is confirmed.
- On Friday, June 26, 2026, the European Commission opened an antitrust probe into French pharmaceutical group Sanofi for allegedly breaching competition rules in marketing its "Efluelda" flu vaccine, primarily in France and Germany.
- The Commission is concerned that Sanofi pursued a misleading communication campaign to disparage the rival "Fluad" vaccine made by CSL Seqirus, portraying it as inferior to Efluelda.
- Antitrust officials allege the campaign targeted healthcare professionals in France and Germany, where Sanofi holds a dominant position; this formal investigation follows unannounced raids on company offices in September 2025.
- If the alleged anticompetitive practices are confirmed, the Commission could impose a fine on Sanofi for abuse of a dominant position, though a spokesperson denied wrongdoing.
- Sanofi stated it is cooperating fully with the European Commission, noting the inquiry "does not in any way prejudge the outcome of the investigation" while emphasizing commitment to fair competition.
Insights by Ground AI
14 Articles
14 Articles
Sanofi Under Scrutiny: EU Probes Vaccine Marketing Tactics
The European Commission has launched an investigation into Sanofi, suspecting it of breaching EU competition rules through a misleading marketing campaign for its flu vaccine, Efluelda. The probe follows raids on Sanofi's offices amidst allegations of disparaging rival brand, Fluad, in France and Germany.
·India
Read Full Article
·New York, United States
Read Full Article
ledauphine.com+2 Reposted by 2 other sources
Health. Influenza Vaccines: EU Opens Investigation Against Sanofi Suspected of Hindering Competition
The French pharmaceutical giant Sanofi is suspected of having abused its dominant position by conducting a campaign of denigration against a vaccine from its Australian competitor.
Coverage Details
Total News Sources14
Leaning Left2Leaning Right1Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
